US Market Potential Aroa's collaboration history with TELA Bio to develop OviTex and prior North American launches position the company to broaden US market access through strategic partnerships, distribution deals, or co-marketing arrangements with hospitals and health systems.

Wound Care Growth The ECM-based soft-tissue regeneration portfolio addresses complex wounds and reconstructive needs, presenting a clear path to expand adoption through clinical evidence, surgeon education, and value-based procurement.

Product Portfolio Synergy Diverse product formats such as Morcells and OviTex allow cross-selling within existing customer bases and may enable expansion into additional indications, settings, and geographies.

Global Expansion With a base in New Zealand and prior international activity, Aroa can accelerate global growth by strengthening distributor networks, pursuing regulatory-ready products, and prioritizing key markets in Australia, North America, and select APAC regions.

Leadership Momentum Leadership changes and ongoing governance improvements can enhance credibility with partners and customers, supporting deeper engagements with healthcare providers and distribution networks.